Risk Factors for Community- & Workplace Transmission of COVID-19

Status Recruiting

Clinical Trial Summary

The project is an epidemiological observational study based on an electronic questionnaire on risk factors for COVID-19 in the community and healthcare setting.

Clinical Trial Description

Summary The data collected will identify real-life risk factors for getting the COVID-19 diagnosis. The Oslo University Hospital/University of Oslo web-based solution "nettskjema" will be used to collect data and consent forms. The impact of knowing the risk factors for COVID-19 is tremendous because it can enable governments to conduct more targeted public health measurements than today to reduce the spread of the virus. Detailed description Research into an ongoing COVID-19 outbreak is difficult because patients are isolated, and supplies of personal protective equipment (PPE) supplies are limited. The risk of transmission to study personal is non-negligible even when PPE is available. A study design based on an electronic questionnaire and consent from delivered from the Oslo University Hospital/University of Oslo, GDPR (General Data Protection Regulation) compliant "TSD" service has therefore been chosen. The study will be a case-control study based on a combined electronic consent form and questionnaire that the participants will fill in using a smartphone and electronic identification. The groups that will be included are: - Hospitalized and non-hospitalized patients/persons with COVID-19 at all stages of the disease and after the disease - Hospitalized patients without COVID-19 - Healthcare personal or other groups with an increased risk of COVID-19 - Healthy volunteers Participants may be followed with repeated questionnaires prospectively. Biological samples Biological samples may hold crucial information about the susceptibility to COVID-19 and for susceptibility to the progression of the disease. It is within the scope of the study to analyze such samples from a limited number of participants which will be asked to provide such samples or hospitalized patients that have surplus material. The material will be analyzed with non-genetic methods most suitable to provide such information. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04320732
Study type	Observational
Source	Oslo University Hospital
Contact	Arne Søraas, MD, PhD
Phone	+4790652904
Email	Arne.Vasli.Lund.Soraas@rr-research.no
Status	Recruiting
Phase
Start date	March 27, 2020
Completion date	March 20, 2030

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05065827` - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting	`NCT05359770` - Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19	N/A
Completed	`NCT04515147` - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19	Phase 2
Not yet recruiting	`NCT06025812` - Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)	N/A
Recruiting	`NCT05289115` - Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS	N/A
Completed	`NCT04779138` - Increasing Vaccine Uptake in Underresourced Public Housing Areas	N/A
Completed	`NCT04953078` - A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19	Phase 1
Not yet recruiting	`NCT05868239` - Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study	N/A
Completed	`NCT04818164` - Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Completed	`NCT04690413` - NOWDx Test for the Detection of Antibodies to COVID-19	N/A
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04572399` - UVA Light Device to Treat COVID-19	N/A
Recruiting	`NCT04610567` - Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)	Phase 1/Phase 2
Recruiting	`NCT04772170` - Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Recruiting	`NCT04581954` - Inflammatory Signal Inhibitors for COVID-19 (MATIS)	Phase 1/Phase 2
Completed	`NCT04405934` - COG-UK Project Hospital-Onset COVID-19 Infections Study	N/A
Enrolling by invitation	`NCT04484025` - SPI-1005 Treatment in Moderate COVID-19 Patients	Phase 2
Completed	`NCT05572840` - Wear Your Mask, Wash Your Hands, Don't Get COVID-19	N/A
Withdrawn	`NCT04838847` - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19	Phase 3
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Risk Factors for Community- and Workplace Transmission of COVID-19

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms